User:ChrisMisu/Generic drug/Bibliography

You will be compiling your bibliography and creating an outline of the changes you will make in this sandbox.

Outline of proposed changes
The entry of generics and biosimilars will now be encouraged by brand-name product companies, reducing the intellectual property hurdles like the “patent dance” for biosimilars. The IRA includes restrictions to prevent the brand name companies from exploiting the entry of generics and biosimilars to assure their independence.